Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 5/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 7/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 6/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534097 | 0.91 | HDAC1 (0.55) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL3318899 | 0.86 | BAZ2B (0.53) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL13781429 | 0.85 | BAZ2B (0.46) | BAZ2BPTGDR2 | |
| SCHEMBL13293449 | 0.84 | BAZ2B (0.49) | BAZ2BHDAC1HDAC6PTGDR2 | |
| SCHEMBL3318937 | 0.84 | BAZ2B (0.59) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL12877321 | 0.83 | HDAC6 (0.54) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL3319833 | 0.83 | BAZ2B (0.58) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL13534105 | 0.83 | BAZ2B (0.58) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL3322108 | 0.83 | BAZ2B (0.60) | BAZ2BHDAC1HDAC6MAOAMAOB | |
| SCHEMBL13534396 | 0.82 | BAZ2B (0.68) | BAZ2BHDAC1HDAC6MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115137-B2 | 2,3,4,5-tetrahydro-1H-pyrido[4,3-B]indole compounds and methods of use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9006263-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2012154261-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-2244708-A1 | NEW 2,3,4,5-TEtRAHYDRO-1H-PYRIDO [4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Medivation Technologies, Inc. (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053366-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | BAZ2B 576/4885HDAC1 1375/4885HDAC6 2844/4885 |
| US-20150266884-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | BAZ2B 576/4885HDAC1 1375/4885HDAC6 2844/4885 |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | BAZ2B 1712/4885HDAC1 3809/4885HDAC6 2802/4885 |
| US-20130053367-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | BAZ2B 664/4885HDAC1 2415/4885HDAC6 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.